Oral Anticoagulation in Patients with Hypertrophic Cardiomyopathy and Non-Valvular Atrial Fibrillation in Japan
DOAC-treated patients had a lower risk of stroke/SE and a comparable risk of bleeding compared with warfarin-treated patients. Prior stroke was shown to augment stroke risk by approximately three-fold. This large real-world study suggests that patients diagnosed with HCM and NVAF can be safely and effectively treated with DOACs in Japan.
Authors
- Natalie Eugene
- Hiroaki Kitaoka
- Robert Carroll (ORCID: https://orcid.org/0000-0003-1561-3769)
- Yukako Matsuo
- Bruno Casaes Teixeira (ORCID: https://orcid.org/0000-0003-2366-0960)
- Toru Kubo
Institutions
- Bristol-Myers Squibb (Germany) (DE)
- Kochi Medical School Hospital (JP)
- Bristol-Myers Squibb (United Kingdom) (GB)
- Bristol-Myers Squibb (Japan) (JP)
- Bristol-Myers Squibb (Italy) (IT)
- Kōchi University (JP)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1002/ehf2.15039
- Citations
- 6
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.41
Funders
- Bristol-Myers Squibb